Company newsForm 8-K

AbCellera Biologics ABCL

AbCellera Biologics shareholders elect two Class III directors

The meeting covered 305,264,947 common shares outstanding and entitled to vote as of the April 15, 2026 record date.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

AbCellera Biologics shareholders elected John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors at the annual meeting held June 11, 2026, for three-year terms expiring at the 2029 annual meeting.

Shareholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved named executive compensation on a non-binding advisory basis.

Key facts

Meeting date
June 11, 2026
Montalbano votes
141,430,732 for, 12,723,342 against, 45,898 abstain
Quake votes
149,019,960 for, 5,113,056 against, 66,956 abstain

All ABCL news

Source: Form 8-K filed June 12, 2026.

Written by GetSignal with AI from the company's SEC filing. How we make news

Not investment advice.

More company news

AbCellera Biologics first, then the newest

All company news